🔗 Share this article

As the United States continues making historic adjustments to its vaccine guidelines, a particular individual has surfaced somewhat surprisingly: Høeg, a Danish American sports medicine doctor and epidemiologist who first made her name by casting doubt on Covid vaccinations throughout the global health crisis and has concentrated on potential fatalities following COVID-19 immunization in her brief time at the FDA.

Planned Overhauls to Childhood Immunization Schedule

Health officials planned to reveal radical revisions to the childhood vaccine schedule recently, bringing the US with the Danish immunization schedule, sources say – a substantial departure that would put the US out of step with much of the international standard with no evidence for public health gain. The announcement has been pushed back until the next year.

Rather than the top vaccines chief, Dr. Høeg is set to present at the gathering. She was newly appointed temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to run the center this calendar year.

A New Direction at the Agency

Høeg's temporary position could signify a tighter collaboration between the drug and biologics branches as Høeg and Dr. Prasad solidify control at the agency – and it suggests a greater focus upon reevaluating long-standing immunizations at the FDA.

Dr. Høeg has often pushed for halting certain pediatric vaccine recommendations in the US so as to align more similar to Denmark, a nation with comprehensive healthcare and a citizenry roughly the size of Wisconsin’s.

In her initial statements, she has persisted in emphasizing on vaccination policy – traditionally the domain of Prasad, director of the FDA’s vaccine center – as opposed to medication approval.

Questions Over Expertise

Høeg has no apparent background in drug development, oversight or management, which has been standard for past heads of the biologics center. She has served at the FDA as a senior adviser to the agency head and the vaccine center since March.

“She appears not to have any of the qualifications” for overseeing the drug-regulation department, stated Jonathan Howard. “She has not conducted a clinical trial. She lacks experience in managing a sizeable institution. She is not an expert in industry regulation.”

Past heads of CBER would “grasp regulatory frameworks and the science of medication creation”, commented a former acting FDA commissioner. “Objectively, she doesn’t have the type of experience that prior appointees who ran the center have had.”

CDER has an vast workload at the FDA, the former commissioner emphasized.

“The public just focuses on the novel medication approvals, but the generic drug division clears thousands of generic medications. There’s a biosimilars division, non-prescription drug unit and other areas, and all of those need to be managed,” Dr. Woodcock said. “The area you neglect, that is the part that I always told people is going to bite you.”

Additionally, a substantial administrative aspect to the job, which oversees in excess of 5,000 employees. “It is a massive leadership role, if you perform it correctly,” Woodcock concluded.

Response and Controversial Initiatives

Regarding questions about Dr. Høeg's qualifications and whether this appointment represents more teamwork among regulatory chiefs on immunizations, a press secretary stated that the “inquiries stem from incorrect presumptions”.

“Her resume aligns with the duties of her role,” the spokesperson stated, pointing to the time Høeg spent advising the FDA commissioner on “pharmaceutical safety and approval science, including computational safety modeling and immunization monitoring”.

As the temporary head, Dr. Høeg takes over the commissioner’s recently launched expedited review system, a disputed one-day medication authorization process that apparently troubled her predecessors. “How are these medications being picked for this voucher program? Who takes the decisions?” Dr. Howard said. “There’s a lot of lack of transparency occurring at the FDA right now.”

In general, he said, “the Food and Drug Administration appears to be shifting towards less stringent rules of all drugs, except for shots.”

Public Track Record on Vaccines

With vaccines, Høeg has a clearer, if troubling, past, some experts observe. She published a study using unconfirmed crowd-sourced reports to estimate the frequency of heart inflammation after COVID-19 vaccination. She counseled the state of Florida surgeon general Joseph Ladapo, who was said to have altered data to imply Covid vaccines are pose a greater threat than they are.

Included in her “wish list” for the new government featured altering guidelines for new vaccines and ending “unnecessary” immunizations, she said post-election on a online show. At the agency, Dr. Høeg has reportedly floated the idea of excluding young men from obtaining Covid vaccines.

“She is an complete true believer who starts off with her beliefs and tailors the evidence to fit the data in a extremely misleading, fraudulent way,” Howard argued.

Consolidating Power and a “Revenge Tour”

Dr. Høeg joined fellow skeptics, {like|